Innovative insights into the effects of a high-sucrose diet on pancreatic health and the therapeutic role of empagliflozin in type 2 diabetes: An experimental study

0Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Type 2 Diabetes (T2D) is a growing global health issue, often aggravated by excessive sugar intake. Chronic high-sucrose diets contribute to insulin resistance, oxidative stress, and pancreatic dysfunction, worsening metabolic health. Sodium-glucose co-transporter 2 (SGLT2) inhibitors, like empagliflozin, show potential in improving glycemic control and metabolic parameters, but their effects on pancreatic efficiency in sugar-induced T2D are not well understood. This study aimed to explore the effects of empagliflozin on metabolic and pancreatic protection in a high-sucrose diet-induced T2D model. Male Wistar rats were divided into four groups: normal, normal-treated, diabetic, and diabetic-treated (n = 8 per group). Diabetes was induced with a 35% sucrose solution for 8 weeks, followed by a low-dose streptozotocin (STZ) injection. Treated groups received empagliflozin (15 mg/kg/day) for the duration. Biochemical markers, including fasting blood sugar (FBS), lipid profile, insulin levels, and oxidative stress markers, were measured. Insulin resistance (HOMA-IR) and pancreatic function (HOMA-B) were assessed. Histological analysis of pancreatic tissues was performed. The high-sucrose diet increased FBS, insulin resistance, and oxidative stress, while decreasing pancreatic function and islet diameter. Empagliflozin treatment lowered FBS (p = 0.001), improved insulin sensitivity (p = 0.001), reduced triglycerides (p = 0.001), and LDL (p = 0.05). It also enhanced antioxidant enzymes, reduced lipid peroxidation (MDA, p = 0.001), and preserved pancreatic islet structure (p = 0.001). A high-sucrose diet negatively affects metabolic health and pancreatic function. Empagliflozin mitigates these effects by improving metabolism, reducing oxidative stress, and preserving pancreatic integrity, suggesting its potential as a therapeutic agent in diabetes related to excessive sugar consumption.

Cite

CITATION STYLE

APA

Gholami, E., Fardin, A., Iranshahi, F., Malek, A., Saravani, A., Aghvami, F., … Yaribeygi, H. (2025). Innovative insights into the effects of a high-sucrose diet on pancreatic health and the therapeutic role of empagliflozin in type 2 diabetes: An experimental study. Animal Models and Experimental Medicine, 8(11), 2091–2098. https://doi.org/10.1002/ame2.70081

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free